Treatment success in cancer: new cancer treatment successes identified in phase 3 randomized controlled trials conducted by the National Cancer Institute-sponsored cooperative oncology groups, 1955 to 2006. Arch Intern Med 2008;168:632e42.Djulbegovic B, Kumar A, Soares HP, Hozo I, Bepler G, ...
The deaths last month of two patients in a clinical trial testing a promising new type of cancer treatment are raising questions about the fate of therapies that use a patient’s own immune cells to fight off the disease. Juno Therapeutics, the Seatt
The importance of including diverse populations in drug and treatment trials has been known for decades; people can respond differently todiagnostic testsor treatments depending upon their sex, age, or racial background, which can affect the quality of treatment they receive. "While a few companies...
The use of this therapy in the last few years has been successful, with a reduction in remission rates of up to 80% for hematologic cancer, particularly for acute lymphoblastic leukemia (ALL) and nonHodgkin lymphomas, such as large B cell lymphoma. Recently, antiCD19 CAR therapy, or UCART...
The CAR T-cell therapy may provide another therapy option for patients with large B-cell lymphoma. CTX110, an allogeneic chimeric antigen receptor (CAR) T-cell therapy for the treatment of relapsed or refractory CD19-positive B-cell malignancies, is well tolerated across a variety of dosing le...
Two studies into deadly cancers in dogs are now underway, offered through the newly formed Clinical Trials Office at Cummings Veterinary Medical Center at Tufts University. Dogs with spontaneous osteosarcoma, as well as dogs with mast cell tumors and sol
There have been major advances in the immunotherapy of cancer in recent years, including the development of T cell engagers — antibodies engineered to redirect T cells to recognize and kill cancer cells — for the treatment of haematological malignancies. However, the field still faces several chal...
REVIEW British Journal of Cancer (2016) 115, 505–516 | doi: 10.1038/bjc.2016.230 Keywords: systemic therapy; metastatic renal cell carcinoma; T-cell checkpoint inhibitors; tyrosine kinase inhibitors Medical treatment of renal cancer: new horizons Basma Greef*,1 and Tim Eisen2 1Department of ...
Search Algorithm to Identify Practice-Influential Phase 3 Cancer Clinical Treatment Trials View LargeDownload FDA indicates US Food and Drug Administration; NCCN, National Comprehensive Cancer Network. Figure 2. Trial Selection Flow Diagram View LargeDownload Figure 3. Disposition of Practice-Influential ...
Chimeric antigen receptor (CAR) T cell therapy, in which a patient’s own T lymphocytes are engineered to recognize and kill cancer cells, has achieved striking success in some hematological malignancies in preclinical and clinical trials, resulting in s